Study
Fine-mapping HLA-II haplotypes in Alzheimer’s disease and healthy longevity reveals distinct associations with microglial HLA-II load and neuropathology
In 6,053 people, distinct HLA-II haplotypes were linked to Alzheimer disease risk, centenarian status, tau pathology, and microglial activation through partly separate pathways.
Summary Do certain immune-system gene patterns affect Alzheimer’s risk and healthy aging? Show / hide ↓
Researchers studied 6,053 people, including 443 healthy centenarians, 3,219 population controls, and 2,391 people with Alzheimer’s disease. They compared haplotypes, which are inherited patterns of gene versions, in a region that helps control the immune system. One pattern was more common in centenarians and controls and was linked to less tau, a protein that builds up in Alzheimer’s disease. Two other patterns were linked to Alzheimer’s risk or to microglia, the brain’s immune cells, showing different effects on brain inflammation. The findings were also checked in a separate brain-bank group, but this was an observational preprint, so it cannot prove that these gene patterns cause disease or longer life.
What this means for you: This does not give you a supplement, test, or treatment to buy. It is useful for understanding Alzheimer’s biology, but it does not change what a healthy person should do today.
early evidenceDaniel Alvarez Sirvent and colleagues fine-mapped seven independent HLA-II haplotypes in 6,053 people: 443 cognitively healthy centenarians, 3,219 population controls, and 2,391 people with Alzheimer disease. Three haplotypes overlapped prior Alzheimer disease or lifespan signals. Hap-B, defined by DRB1*04 subtypes, was enriched in centenarians and controls relative to Alzheimer disease and its association with tau pathology was replicated in an independent Netherlands Brain Bank cohort. Hap-R, DRB1*01:01, was associated with higher Alzheimer disease risk and lower healthy-longevity status, alongside lower microglial HLA-II activation. Hap-Y, DRB1*15:01, was linked to higher microglial HLA-II activation independent of quantitative Alzheimer neuropathology. The result supports a relationship between HLA architecture, brain immune state, and healthy longevity. It is a preprint and an observational genetic study. It identifies mechanisms and risk associations, not a supplement target or a proven intervention.
These findings indicate distinct HLA-II haplotypes shape AD susceptibility and healthy longevity through separate mechanisms, linking HLA architecture to brain immune states beyond classical neuropathology.
Preprint, not peer reviewed. Genetic associations do not establish that changing HLA-II activity would extend lifespan. Centenarian comparisons can be affected by survival, ancestry, and selection bias.